


REMARKS

Applicants have attached an abstract on a separate sheet of paper as required by U.S. practice. Applicants have amended the specification for purposes of adding the priority information. Claims 5, 7, and 10 were amended to correct typographical errors. Claim 10 was amended to depend from claim 7. Support for the amendment is provided in the specification at page 5. Claims 12, 13, and 14 have been amended to remove multiple dependencies. Claims 19 - 24 have been added. Support for new claims 19 - 24 is provided in the specification at pages 5 and 7. Claims 1 - 7, and 10 - 24 are pending in the application. No new matter has been added. It is respectfully submitted that the present application is in condition for allowance. An early consideration and notice of allowance are earnestly solicited.

Respectfully submitted,

Date: 12-13-05


Karen L. Prus
Attorney of Record, Reg. No 39,337

GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398
Telephone: 919-483-2192
Fax: 919-483-7988